❌

Normal view

Received β€” 15 September 2026 ⏭

Advanced and underlying therapeutic strategies in transformed small cell lung cancer

βœ‡Omics In Lung
By: Mingfeng Wei Β· Zheng Li Β· Kaiyuan Zhu Β· Shixiang Guo Β· Lefei Hu Β· Fuzhi Yang Β· Xiaoyu Chen Β· Xuelin Zhang Β· Shuai Jiang Β· Xunxia Zhu Β· Xiaoyong Shen
11 September 2026 at 18:00

Front Med (Lausanne). 2026 Aug 27;13:1865050. doi: 10.3389/fmed.2026.1865050. eCollection 2026.

ABSTRACT

Transformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9-13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy remains the gold standard for confirming histologic transformation, whereas molecular profiling and liquid biopsy may facilitate early detection and longitudinal disease monitoring. Platinum-etoposide remains the most commonly used clinical standard after transformation, but its benefit is typically transient and durable disease control remains uncommon. Continuation of EGFR tyrosine kinase inhibitors combined with chemotherapy may prolong progression-free survival in selected patients but has not consistently improved overall survival. Anti-angiogenic therapy, particularly anlotinib, and chemo-immunotherapy have shown encouraging activity in selected patients, while emerging strategies targeting DLL3, MYC, SOX2, and epigenetic regulators may broaden the therapeutic landscape. Prospective studies integrating repeat tissue sampling, comprehensive genomic profiling, biomarker-guided patient stratification, pharmacogenomics, functional drug-sensitivity testing where feasible, and integrated multi-omics approaches are needed to advance molecularly guided and individualized treatment for T-SCLC.

PMID:42724635 | PMC:PMC13560167 | DOI:10.3389/fmed.2026.1865050

Received β€” 13 September 2026 ⏭

Advanced and underlying therapeutic strategies in transformed small cell lung cancer

βœ‡(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
By: Mingfeng Wei Β· Zheng Li Β· Kaiyuan Zhu Β· Shixiang Guo Β· Lefei Hu Β· Fuzhi Yang Β· Xiaoyu Chen Β· Xuelin Zhang Β· Shuai Jiang Β· Xunxia Zhu Β· Xiaoyong Shen
11 September 2026 at 18:00

Front Med (Lausanne). 2026 Aug 27;13:1865050. doi: 10.3389/fmed.2026.1865050. eCollection 2026.

ABSTRACT

Transformed small-cell lung cancer (T-SCLC) is a clinically important form of histologic transformation and a mechanism of acquired resistance in non-small-cell lung cancer (NSCLC). It is associated with poor prognosis, with a median overall survival of only about 9-13 months. This review summarizes recent advances in the mechanisms, diagnosis, monitoring, and treatment of T-SCLC. Repeat biopsy remains the gold standard for confirming histologic transformation, whereas molecular profiling and liquid biopsy may facilitate early detection and longitudinal disease monitoring. Platinum-etoposide remains the most commonly used clinical standard after transformation, but its benefit is typically transient and durable disease control remains uncommon. Continuation of EGFR tyrosine kinase inhibitors combined with chemotherapy may prolong progression-free survival in selected patients but has not consistently improved overall survival. Anti-angiogenic therapy, particularly anlotinib, and chemo-immunotherapy have shown encouraging activity in selected patients, while emerging strategies targeting DLL3, MYC, SOX2, and epigenetic regulators may broaden the therapeutic landscape. Prospective studies integrating repeat tissue sampling, comprehensive genomic profiling, biomarker-guided patient stratification, pharmacogenomics, functional drug-sensitivity testing where feasible, and integrated multi-omics approaches are needed to advance molecularly guided and individualized treatment for T-SCLC.

PMID:42724635 | PMC:PMC13560167 | DOI:10.3389/fmed.2026.1865050

Received β€” 8 April 2026 ⏭

Fine-grained Analysis of Stability and Generalization for Stochastic Bilevel Optimization

βœ‡cs.AI, q-bio.NC updates on arXiv.org
By: Xuelin Zhang Β· Hong Chen Β· Bin Gu Β· Tieliang Gong Β· Feng Zheng
7 April 2026 at 12:00
arXiv:2604.04090v1 Announce Type: cross Abstract: Stochastic bilevel optimization (SBO) has been integrated into many machine learning paradigms recently, including hyperparameter optimization, meta learning, and reinforcement learning. Along with the wide range of applications, there have been numerous studies on the computational behavior of SBO. However, the generalization guarantees of SBO methods are far less understood from the lens of statistical learning theory. In this paper, we provide a systematic generalization analysis of the first-order gradient-based bilevel optimization methods. Firstly, we establish the quantitative connections between the on-average argument stability and the generalization gap of SBO methods. Then, we derive the upper bounds of on-average argument stability for single-timescale stochastic gradient descent (SGD) and two-timescale SGD, where three settings (nonconvex-nonconvex (NC-NC), convex-convex (C-C), and strongly-convex-strongly-convex (SC-SC)) are considered respectively. Experimental analysis validates our theoretical findings. Compared with the previous algorithmic stability analysis, our results do not require reinitializing the inner-level parameters at each iteration and are applicable to more general objective functions.
There are no more articles
❌